ArticleHuman vaccines & immunotherapeutics2016

Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?

Gennaro Riccio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.